Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday

Corbus Pharmaceuticals (NASDAQ:CRBP) is projected to post its quarterly earnings results before the market opens on Tuesday, March 11th. Analysts expect Corbus Pharmaceuticals to post earnings of ($1.02) per share for the quarter.

Corbus Pharmaceuticals Price Performance

NASDAQ CRBP opened at $6.96 on Tuesday. The firm’s fifty day moving average price is $10.47 and its 200 day moving average price is $21.71. The company has a market capitalization of $84.77 million, a price-to-earnings ratio of -1.48 and a beta of 2.63. Corbus Pharmaceuticals has a 12 month low of $6.78 and a 12 month high of $61.90.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. William Blair started coverage on shares of Corbus Pharmaceuticals in a research report on Friday. They issued an “outperform” rating on the stock. StockNews.com upgraded shares of Corbus Pharmaceuticals to a “sell” rating in a research note on Monday, January 13th. HC Wainwright reiterated a “buy” rating and set a $75.00 price target on shares of Corbus Pharmaceuticals in a research note on Tuesday, February 18th. Piper Sandler started coverage on shares of Corbus Pharmaceuticals in a research note on Monday, December 2nd. They set an “overweight” rating and a $35.00 price target for the company. Finally, Wedbush reiterated an “outperform” rating and set a $51.00 price target on shares of Corbus Pharmaceuticals in a research note on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Corbus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $61.38.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.